NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is funded by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address the challenge of maintaining therapeutic drug concentrations within brain tumors. While convection-enhanced delivery (CED) bypasses the blood-brain barrier, drugs are often cleared rapidly from the treatment site. The Mayo Clinic team will evaluate a combination therapy strategy to enhance intratumoral drug retention by modulating drug efflux mechanisms, potentially prolonging therapeutic exposure. The project begins with large animal studies and may expand to human trials if successful.
The study will use NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy while providing real-time physiologic monitoring, offering insights into drug delivery and effects on the surrounding neural environment.
The CCRF award is a milestone in advancing this therapeutic approach toward clinical evaluation. The collaboration expands NeuroOne's drug delivery initiatives and reflects growing interest from academic investigators and biopharmaceutical companies in the company's platform. David Wambeke, Chief Business Officer of NeuroOne, stated, "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording."
NeuroOne markets a minimally invasive electrode technology platform with FDA-cleared products, including the Evo® Cortical Electrodes and OneRF® Ablation System. The company is also researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation. For more information, visit nmtc1.com.
